Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,982 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07008287Recruiting
Taletrectinib for ROS1+ lung cancer with brain spread
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hangzhou, ZhejiangAges 18 years+ - NCT07008742Recruiting
Blood and tissue collection study for certain lung cancers
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
London, United KingdomAges 18 years+ - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07014202RecruitingPhase 2
Radiation therapy after chemo-immunotherapy for lung cancer
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07014410RecruitingPhase 2
Pyrotinib, dalpiciclib, and letrozole for advanced breast cancer
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT07016672Recruiting
PRP vs. hyaluronic acid for advanced knee arthritis
This study compares two treatments—platelet-rich plasma (PRP) and hyaluronic acid (a lubricating injection)—for people with severe knee arthritis seen on MRI. The goal is to see which better reduces pain.
Toulon, VarAges 18 years+ - NCT07016724RecruitingPhase 2
Study of radiation and chemo with cadonilizumab for esophageal cancer
This trial tests combining radiation, chemotherapy, and the drug cadonilizumab before surgery for locally advanced esophageal squamous cell cancer. It aims to shrink the tumor and improve treatment outcomes.
Zhengzhou, HenanAges 18–75 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07018570RecruitingPhase 2
Chemo, immunotherapy, and radiation for stomach cancer before surgery
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Kashiwa, ChibaAges 18 years+ - NCT07021820Recruiting
New light-based imaging for centronuclear myopathy
This study tests a new type of imaging that uses light and sound to look at muscles in people with centronuclear myopathy. It may help doctors see muscle changes more clearly. It does not involve any treatment or medicine.
Erlangen, BavariaAges 2 years+ - NCT07021898RecruitingPhase 1
ERAS-4001 for advanced solid tumors with mutations
This trial tests a new oral drug called ERAS-4001 for people with advanced solid tumors that have a specific genetic change and are no longer helped by standard treatments. It aims to see if the drug is safe and can shrink tumors.
Nashville, TennesseeAges 18–99 - NCT07022535RecruitingPhase 2
Personalized timing of surgery for advanced ovarian cancer
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Hong KongAges 18 years+ - NCT07023484RecruitingPhase 2
Timing of ovarian cancer surgery after chemo
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
GuangzhouAges 18 years+ - NCT07024680Recruiting
Sunitinib or sorafenib for papillary kidney cancer
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07025174RecruitingPhase 2
Sequential anti-angiogenic therapy after immunotherapy for advanced bile duct cancer
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
Hangzhou, ZhejiangAges 18–75 - NCT07027514RecruitingPhase 1
Study of Tolododekin Alfa with immunotherapy for advanced lung cancer
This trial tests a new drug, Tolododekin Alfa, combined with an immunotherapy drug for advanced non-small cell lung cancer. It aims to see if this combination can help shrink tumors and improve outcomes.
Indianapolis, IndianaAges 18 years+ - NCT07028021Recruiting
Water turnover study of the Chinese population
This study measures water turnover in healthy Chinese adults using a safe deuterium dilution method. It aims to understand normal body water regulation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT07031830Recruiting
Physical activity program for advanced melanoma patients
This trial tests whether an adapted physical activity program can help patients with advanced melanoma who are receiving immunotherapy or targeted therapy. It aims to support overall well-being during treatment.
RouenAges 18 years+ - NCT07031921Recruiting
Ultrasound image bank for medical research
This study is building a collection of ultrasound images to help doctors and researchers learn more about different conditions. By joining, you allow your ultrasound images to be used for future medical research.
RomaAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,982 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.